216,707 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Purchased by Weiss Asset Management LP

Weiss Asset Management LP bought a new stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 216,707 shares of the biotechnology company's stock, valued at approximately $893,000. Weiss Asset Management LP owned approximately 0.14% of Ironwood Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Robeco Institutional Asset Management B.V. lifted its position in Ironwood Pharmaceuticals by 1,293.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 380,960 shares of the biotechnology company's stock worth $1,570,000 after acquiring an additional 353,624 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Ironwood Pharmaceuticals by 150.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,289 shares of the biotechnology company's stock worth $520,000 after acquiring an additional 75,917 shares during the period. Pacer Advisors Inc. lifted its position in Ironwood Pharmaceuticals by 26.6% during the 3rd quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company's stock worth $46,473,000 after acquiring an additional 2,372,183 shares during the period. KBC Group NV lifted its position in Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 3,198 shares during the period. Finally, Walleye Capital LLC lifted its position in Ironwood Pharmaceuticals by 264.2% during the 3rd quarter. Walleye Capital LLC now owns 280,299 shares of the biotechnology company's stock worth $1,155,000 after acquiring an additional 203,331 shares during the period.

Ironwood Pharmaceuticals Trading Up 16.0 %

Shares of NASDAQ IRWD traded up $0.55 during trading on Monday, reaching $3.98. 2,597,509 shares of the company traded hands, compared to its average volume of 2,842,510. The firm's fifty day simple moving average is $4.06 and its 200 day simple moving average is $5.07. The stock has a market cap of $636.92 million, a P/E ratio of -124.67 and a beta of 0.41. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.06 and a 12-month high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $91.60 million during the quarter, compared to analysts' expectations of $91.22 million. During the same quarter in the prior year, the firm earned $0.12 EPS. Ironwood Pharmaceuticals's revenue for the quarter was down 19.4% on a year-over-year basis. As a group, research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current year.

Insider Activity at Ironwood Pharmaceuticals

In related news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76. The trade was a 3.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

IRWD has been the subject of a number of research reports. Leerink Partners initiated coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a "market perform" rating and a $5.00 price target for the company. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a "hold" rating in a research note on Monday, September 9th. Finally, StockNews.com lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $10.40.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.